A One Year Survey on the Epidemiology of Aminoglycoside Resistance in a General Hospital: Influence of Amikacin.
R. Vanhoorf, Jelena Hubrechts, E. Roebben, Mathias Claeys, Eric Nulens, H.-J. Nyssen, M. Van Haeverbeek, J.-P. Van Gysel
Abstract
R. Vanhoorf, Jelena Hubrechts, E. Roebben, Mathias Claeys, Eric Nulens, H.-J. Nyssen, M. Van Haeverbeek, J.-P. Van Gysel
Abstract
SummaryIn a 15 month period we have studied the epidemiology of aminoglycoside resistance in ai general hospital. We determined the effect of preferential amikacin usage on the resistance levels of amikacin, gentamicin, tobramycin, netilmicin and dibekacin. The resistance levels’ to each of these antibiotics were monitored in a> 3 month baseline phase during which amikacin usage was less than 1 %. During the remainder 12 months, amikacin was the aminoglycoside of choice and in this period no significant change in aminoglycoside resistance was noted. Nevertheless some changes in the combined resistance were found. From the aminoglycoside resistant strains only 8.8 % showed resistance to amikacin. Isolated amikacin resistance was not found and amikacin resistant strains showed cross-resistance to nearly all the other aminoglycosides.
OpenAlex reports 2 citations for this work. Citation counts describe recorded attention and do not establish research quality.
A contribution statement is not available in the OpenAlex record.
Method details are not available in the OpenAlex metadata.
Findings are not separately available in the OpenAlex metadata.
Limitations are not available in the OpenAlex metadata.
Application details are not available in the OpenAlex metadata.
SummaryIn a 15 month period we have studied the epidemiology of aminoglycoside resistance in ai general hospital. We determined the effect of preferential amikacin usage on the resistance levels of amikacin, gentamicin, tobramycin, netilmicin and dibekacin. The resistance levels’ to each of these antibiotics were monitored in a> 3 month baseline phase during which amikacin usage was less than 1 %. During the remainder 12 months, amikacin was the aminoglycoside of choice and in this period no significant change in aminoglycoside resistance was noted. Nevertheless some changes in the combined resistance were found. From the aminoglycoside resistant strains only 8.8 % showed resistance to amikacin. Isolated amikacin resistance was not found and amikacin resistant strains showed cross-resistance to nearly all the other aminoglycosides.
Key concepts: Amikacin, Netilmicin, Aminoglycoside, Tobramycin, Medicine, Gentamicin, Antibiotics, Microbiology